
TC Biopharm (holdings) PLC
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States. Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections, as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Stock Performance (90 Days)
Layoff History
Recent News
Other Biotechnology Companies
View All →Frequently Asked Questions
Has TC BioPharm (Holdings) plc had layoffs?
How many employees does TC BioPharm (Holdings) plc have?
What industry is TC BioPharm (Holdings) plc in?
Is TC BioPharm (Holdings) plc a publicly traded company?
Where is TC BioPharm (Holdings) plc headquartered?
Disclaimer
Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.
This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.
Found an error? Report it here.